6.56
Climb Bio Inc Borsa (CLYM) Ultime notizie
Climb Bio, Inc. 8-K Filing Details: Company Information, Address, and Stock Exchange Listing (April 2026) - Minichart
Climb Bio announces departure of finance SVP and appointment of new accounting officer - Investing.com
Climb Bio's recently appointed CFO is unlikely to make a significant impact—what truly matters is the clinical data. - bitget.com
Climb Bio Consolidates Financial Leadership After SVP Departure - TipRanks
Climb Bio (CLYM) consolidates CFO and principal accounting officer roles - Stock Titan
Climb Bio (CLYM) price target increased by 34.43% to 15.67 - msn.com
CLYM Stock Price, Quote & Chart | CLIMB BIO INC (NASDAQ:CLYM) - ChartMill
Piper Sandler initiates coverage of Climb Bio (CLYM) with overweight recommendation - MSN
Climb Bio, Inc. (NASDAQ:CLYM) Receives Consensus Recommendation of "Buy" from Analysts - marketbeat.com
Climb Bio, Inc.Common Stock (NQ: CLYM - The Chronicle-Journal
Climb Bio (NASDAQ:CLYM) Raised to Strong-Buy at B. Riley Financial - MarketBeat
B Riley Securities initiates coverage of Climb Bio (CLYM) with buy recommendation - MSN
B. Riley Securities Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $26 - Moomoo
B. Riley Financial Initiates Coverage on Climb Bio (NASDAQ:CLYM) - MarketBeat
B.Riley initiates Climb Bio stock with buy rating on kidney drug potential - Investing.com
B.Riley initiates Climb Bio stock with buy rating on kidney drug potential By Investing.com - Investing.com Australia
If You Invested $1,000 in Climb Bio (CLYM) - Stock Titan
Aug Breakouts: Is Climb Bio Inc forming a double bottom2026 Technical Patterns & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Climb Bio (NASDAQ:CLYM) Upgraded by Truist Financial to Strong-Buy Rating - MarketBeat
Is Climb Bio, Inc. (CLYM) Outperforming Other Medical Stocks This Year? - MSN
Climb Bio (CLYM) Receives 'Buy' Rating from Truist Securities | - GuruFocus
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
Truist initiates Climb Bio stock with buy rating on drug potential - Investing.com Australia
Truist initiates Climb Bio stock with buy rating on drug potential By Investing.com - Investing.com South Africa
Climb Bio (CLYM) Expected to Announce Quarterly Earnings on Tuesday - marketbeat.com
Climb Bio Highlights Budoprutug and CLYM116 Milestones, Sets Up “Rich Data Year” in 2026 - MarketBeat
HC Wainwright Has Pessimistic View of Climb Bio Q1 Earnings - Defense World
Pharma News: Will Climb Bio Inc benefit from green energy policiesMarket Risk Report & Growth-Oriented Investment Plans - baoquankhu1.vn
Targets Report: Can Climb Bio Inc sustain its profitability2026 Action & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Raymond James initiates coverage of Climb Bio (CLYM) with strong buy recommendation - MSN
What is HC Wainwright's Forecast for Climb Bio Q1 Earnings? - MarketBeat
Raymond James starts Climb Bio, Inc. (CLYM) at Strong Buy March 2026 - Meyka
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):